Posts for Ticker ‘ZGEN’

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted on: May 27, 2009 – 1:34 pm in Biotech, Drug companies, FDA, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ZymoGentics Backers File To Sell Stock (ZGEN, NVO)

ZymoGenetics, Inc. (NASDAQ: ZGEN) has filed an SEC registration which would allow the company to sell up to $100 million of its common stock from time to time. What is important to note is that this is intended to replace the company’s previously filed shelf registration statement set to expire on December 1, 2008.  What is also important to note is that the filing is essentially of little benefit to the company.

Read More »

Posted on: November 25, 2008 – 4:53 pm in Biotech, Insider Activity, Secondary Offering, ,

Top Analyst Upgrades & Downgrades (CEG, DENN, ODSY, ARO, D, EXEL, JNJ, VOCS, ZGEN)

These are some of the other non-tech analyst upgrades and downgrades from Wall Street firms this Wednesday morning:

  • Constellation Energy (CEG) Raised to Buy at Jefferies.
  • Denny’s (DENN) Raised to Buy at Merriman Curhan Ford.
  • Odyssey Healthcare (ODSY) Raised to Neutral at JPMorgan.
  • Aeropostale (ARO) Cut to Market Perform at FBR.
  • Dominion Resources (D) Cut to Underperform at Jefferies.
  • Exelixis (EXEL) Cut to Neutral at Piper Jaffray.
  • Johnson & Johnson (JNJ) Cut to Neutral at JPMorgan.
  • Vocus (VOCS) Cut to Neutral at Piper Jaffray.
  • Zymogenetics (ZGEN) Cut to Neutral at Piper Jaffray.

Here are the technology upgrades and downgrades.

Jon C. Ogg
October 29, 2008

Posted on: October 29, 2008 – 7:08 am in Analyst Calls, , , , , , , , ,

Select Positive ASCO Data (ARRY, AZN, LLY, DNA, GSK, ONXX, PFE, ZGEN)

Last night was a novel release from the American Society of Clinical Oncology (or ASCO) as the society decided to publish all of the findings to the public at once.  Keep in mind that many of the larger drug companies will have other presentations as well.  Below is some of the key and very brief data:

Array BioPharma (NASDAQ: ARRY) and AstraZeneca have announced plans for two additional randomized Phase II trials for AZD6244 in the second half of 2008 to test AZD6244 (ARRY-886) in combination with a chemotherapeutic agent; one trial will be for melanoma patients and the other for non-small cell lung cancer patients.  AstraZeneca (NYSE: AZN) showed positive breast cancer data in survivability.

Eli Lilly (NYSE: LLY) showed that its Alimta showed 3 months longer survival in a lung cancer sub-set group.

Genentech (NYSE: DNA) showed that Avastin in brain cancer trials showed 9 months survival while most patients live only 6 months from the study point.

GlaxoSmithKline (NYSE: GSK) showed that Tykerb added 1 year survival on advanced breast cancer patients.

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and Bayer HealthCare Pharmaceuticals announced that Nexavar tablets significantly improved overall survival by 47.3% in patients in the Asia-Pacific region with primary liver cancer versus those receiving placebo; Nexavar improved time to progression in these patients by 74%.

Pfizer (NYSE: PFE) presented data showing Celebrex may prevent lung cancer in current and former smokers.

ZymoGenetics, Inc. (NASDAQ: ZGEN) showed additional data from Phase 1 confirm that the combination is well-tolerated and shows anti-tumor activity; also reported positive results from the cohort expansion portion of a Phase 1 study with IL-21 and Rituxan in relapsed/refractory indolent lymphoma.

In the past investors had to wait for abstracts to be published and for presentations to be made.  It also was a situation where embargoes were used with media on releasing certain data.  Needless to say, there were many leaks on key data on who got what information when… and many profited from it.

This is only a brief summary of data from only a handful of the companies.  You can count on there being more data from many more biotech and drug companies… Floods of it.

Jon C. Ogg
May 16, 2008

Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.

Posted on: May 16, 2008 – 7:26 am in Biotech, , , , , , , , , ,

Pre-Market Stock News (June 19, 2007)

(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.
(BAY) Bayer raised guidance on Schering integration.
(BMY) Bristol-Myers: FDA Grants Priority Review for Bristol-Myers Squibb’s Investigational Oncology Treatment Ixabepilone.
(BTU) Peabody Energy was named Cramer’s favorite pick in the coal sector.
(CLRK) Color Kinetics trading up 11% at $33.00+ on $34 buyout from Philips Electronics.
(CPKI) California Pizza Kitchen trades ex-split today to reflect a 3-2 stock Split.
(CUB) Cubic received a $468 million contract to give mission support to Army readiness training center.
(DAL) Delta is considering a 125 Boeing order for Dreamliners.
(DJ) Dow Jones may get a bid from billionaire Ron Burkle.
(EXPE) Expedia buying back $3.5 Billion in stock.
(FDS) FactSet $0.52 EPS vs $0.51 estimate.
(GE) GE buying controlling stake in natural gas pipeline Regency for $603 million.
(INO) Inovio Biomedical’s selective electrochemical tumor ablation therapy demonstrated safety, tolerability, and complete responses in breast cancer study.
(LNET) LodgeNet noted positively by Cramer on Mad Money.
(MRO) Marathon Oil trades ex-split today to reflect a 2-1 stock split.
(PRGS) Progress Software $0.45 EPS vs $0.41e.
(STR) Questar trades ex-split to reflect a 2-1 stock split.
(SGMO) Sangamo BioScience reached milestones in agriculture collaboration with Dow AgroSciences.
(SIRI) SIRIUS signed Volkswagen as standard equipment on all Touareg, New Beetle, New Beetle Convertible, GTI, and GLI sales for the 2008 models.
(TASR) TASER announced foreign order for 1,375 devices.
(TSN) Tyson making product announcementthis morning.
(YHOO) Yahoo! trading up 8% after Semel stepped down as CEO and co-founder Jerry Yang came back as CEO; Semel remaining non-executive Chairman.
(ZGEN) ZymoGenetics entered a global collaboration pact with Bayer for development and commercialization of recombinant human thrombin.

Jon C. Ogg
June 19, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 19, 2007 – 7:11 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , ,

Earlybird Analyst Calls (June 14, 2007)

ACL started as Buy at Jefferies.
AMGN started as Mkt Perform at Rodman & Renshaw.
B started as Outperform at CIBC.
CBB started as Buy at UBS.
CHE started as Buy at Jefferies.
CTL raised to Neutral at UBS.
CYTX started as Mkt Perform at Piper Jaffray.
DJ cut to Reduce at UBS.
EQ raised to Buy at UBS.
ESI cut to Equal Weight at Lehman.
EYE started as Underperform at Jefferies.
GNLB started as Buy at Oppenheimer.
ILMN raised to Outperform at Bear Stearns.
ISIL raised to Buy at B of A.
MFA started as Outperform at JMP Securities.
MNKD started as Buy at B of A.
OPTT started as Outperform at Bear Stearns.
PT raised to Outperform at Credit Suisse.
RACK started as Buy at Merriman Curhan Ford.
RBC started as Sector Perform at CIBC.
SLM cut to Peer Perform at Bear Stearns.
SNY cut to Neutral at HSBC; cut to Neutral at JPMorgan.
THI raised to Outperform at CIBC.
VDSI cut to Hold at Jefferies.
VTIV raised to Strong Buy at First Albany.
WIN started as Neutral at UBS.
ZGEN started as Neutral at Oppenheimer.

Jon C. Ogg
June 14, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 14, 2007 – 6:29 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , , , , ,